Study Results Of Gammagard S D And Gammagard Liquid In Patients With Mild-To-Moderate Alzheimer's Disease Announced
Presbyterian Hospital/Weill Cornell Medical Center and Baxter International Inc. (NYSE: BAX) announced results of a six-month, placebo-controlled Phase II study of 24 patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID [Immune Globulin Intravenous (IGIV)] for the treatment of mild-to-moderate Alzheimer's disease today at the American Academy of Neurology (AAN) annual meeting in Chicago.
Dementia Now A National Priority: Alzheimer Scotland Welcomes Ministerial Statement
Today's Ministerial statement on dementia by Shona Robison MSP is warmly welcomed by Alzheimer Scotland. It confirms that the Scottish Government recognises the scale of the problem of dementia in Scotland, as highlighted by our recent report The Dementia Epidemic - where Scotland is now and the challenge ahead.
Alzheimer Scotland Welcomes Promising Early Findings From Tarenflurbil Study
Alzheimer Scotland welcomes the recent findings from Professor Gordon Wilcock's randomised phase II trial of tarenflurbil in patients with mild to moderate Alzheimer's Disease, but cautions that the phase III stage will be crucial in ascertaining its true potential.
Presentations From 'Intracellular Traffic And Neurodegenerative Disorders' Meeting
The 23rd Colloque Medecine et Recherche of La Fondation Ipsen dedicated to the Alzheimer series was held in Paris on 28 April 2008. Entitled "Intracellular Traffic and Neurodegenerative Disorders" this meeting gathered fourteen leading researchers focused on the intracellular world.
Study Results Of GAMMAGARD S D And GAMMAGARD LIQUID In Patients With Mild To Moderate Alzheimer's Disease Announced
New York-Presbyterian Hospital/Weill Cornell Medical Center and Baxter International Inc. (NYSE: BAX) announced results of a six-month, placebo-controlled Phase II study of 24 patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID [Immune Globulin Intravenous (IGIV)] for the treatment of mild-to-moderate Alzheimer's disease today at the American Academy of Neurology (AAN) annual meeting in Chicago.
Affiris Develops Alzheimer's Vaccine
The Viennese biotech company Affiris is taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well.
Alzheimer's Starts Earlier For Heavy Drinkers, Smokers
Heavy drinkers and heavy smokers develop Alzheimer's disease years earlier than people with Alzheimer's who do not drink or smoke heavily, according to research that will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12-19, 2008.
Antioxidant Therapy Shows Early Promise Against Alzheimer's Disease - Improved Blood Flow Boosted Cognition And Behavior In Mice With AD-Like Illness
For the first time, new research demonstrates that curbing harmful antioxidant processes in the brain's vasculature can reverse some of the cognitive decline associated with Alzheimer's disease. A natural enzyme of the immune system -- NADPH oxidase -- has been found to have toxic side effects, producing free radicals in the brains of mice.
Alzheimer's Patients On Experimental Drug Showed Improved Mental Skills After One Year
Patients with mild to moderate Alzheimer's disease who were treated with the experimental drug Dimebon from US drugmaker Medivation Inc, showed improvement in key mental skills after a year compared to patients who took the placebo. The patients on the active drug showed clear improvements in memory, language, awareness of time and place, and a more complex process called "praxis", which means having an idea and then actually putting it into practice.
Alzheimer's Society Comment On Reducing Your Risk Of Developing Dementia, UK
It is important that people lead a healthy lifestyle to reduce their risk of developing dementia. This research adds to the weight of evidence on drinking and smoking habits and the risk of developing dementia. Smoking, drinking heavily and having high cholesterol can all lead to an increased risk of developing this devastating condition and the risk is further increased for individuals with a particular genetic variant.